Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Actemra intravenous for the treatment of COVID-19 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation. "Actemra is the first FDA-approved monoclonal antibody to treat COVID-19 and is recommended for use as a single 60-minute IV infusion," the company stated. "With new variants emerging, FDA-approved treatments including Actemra remain essential to the continued fight against COVID-19. Actemra is the first FDA-approved monoclonal antibody for treating patients with severe COVID-19, providing an important option for hospitalized patients and their healthcare providers who continue to be on the frontlines treating COVID-19," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- FDA approves Roche’s Actemra for the treatment of COVID-19 in hospitalised adults
- Biogen reaches agreement with Genentech related to glofitamab commercialization
- Roche says CHMP recommends expansion of EU label for Hemlibra
- CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia A
- Adagene announces clinical trial collaboration with Roche
